Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024

Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions.2020 to 2024

Companion Diagnostics and Liquid Biopsy drive market growth while lowering costs. COVID causes resources shift.....

Report Overview:

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report from Howe Sound Research. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health
Working against this dynamic market are the forces of the COVID Driven Recession. Our latest numbers factor in the different COVID forces and their timing. And their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

" Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

All report data is available in Excel format on request.

i. Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Driven Recession
ii. Guide for Executives, Marketing, Sales and Business Development Staff
iii. Guide for Management Consultants and Investment Advisors
1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing
2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT
3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 Testing as a Controllable Cost
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing
3.4.2 Shifting Role of Diagnostics
3.4.3 Multiplexing and Foundation One
3.4.4 Pharmacogenomics Technology
3.4.5 Whole Genome Sequencing
3.4.6 Gene Editing and Gene Therapy
4. Molecular Diagnostics Recent Developments
Recent Developments – Importance and How to Use This Section
Importance of These Developments
How to Use This Section
Coronavirus Pandemic Bites into European Cancer Research
Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
Combining CRISPR and Nanopore Sequencing
Liquid Biopsy Detects Cancer Early via Cell Clusters
Roche, Illumina unveil 15-year cancer diagnostic tie-up
Saga, Servier Sign Liquid Biopsy Services Deal
Home urine test could revolutionize diagnosis of prostate cancer
Cancer Gene Tests Cost-Effective for Breast Cancer Patients
Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
OncoCyte to Buy Cancer Testing Company Razor Genomics
Blood Test May Eliminate Need for Exploratory Surgery
NGS Cancer Panel Receives New York State Conditional Approval
Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb
Icon Acquires MolecularMD
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune
Profiling Business
Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health
UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
Guardant Health, Core Diagnostics to Offer Liquid Biopsy in India
Invitae Q3 Revenues More Than Double
Illumina to Acquire Pacific Biosciences
Lung Cancer Panel From PlexBio Receives CE Mark
5. Profiles of Key MDx Companies
10x Genomics, Inc.
Abbott Diagnostics
AccuraGen Inc
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience, Inc
Anchor Dx
ApoCell, Inc.
ArcherDx, Inc.
ARUP Laboratories
AVIVA Biosciences
Baylor Miraca Genetics Laboratories
Beckman Coulter, Inc.
BGI Genomics Co. Ltd
Bioarray Genetics
Biocept, Inc
Biodesix Inc.
Biolidics Ltd
bioMérieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc
Bio-Reference Laboratories
Boreal Genomics
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Cepheid (now Danaher)
Charles River Laboratories
Chronix Biomedical
Clinical Genomics
Cytolumina Technologies Corp.
Datar Cancer Genetics Limited
Diagnologix LLC
Diasorin S.p.A.
Enzo Life Sciences, Inc.
Epic Sciences
Epigenomics AG
Eurofins Scientific
Exosome Diagnostics
Exosome Sciences
Fabric Genomics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
FUJIFILM Wako Diagnostics
GeneFirst Ltd.
Genetron Health (Beijing) Co., Ltd
Genomic Health
GILUPI Nanomedizin
Grail, Inc.
Guardant Health
Horizon Discovery
HTG Molecular Diagnostics
Incell Dx
Integrated Diagnostics
Janssen Diagnostics
MDx Health
Menarini Silicon Biosystems
Millipore Sigma
Miltenyi Biotec
miR Scientific
Molecular MD
Myriad Genetics/Myriad RBM
NantHealth, Inc.
New Oncology
Novogene Bioinformatics Technology Co., Ltd.
Ortho Clinical Diagnostics
Oxford Nanopore Technologies
Perkin Elmer
Personal Genome Diagnostics
Qiagen Gmbh
Rarecells SAS
Roche Molecular Diagnostics
Sense Biodetection.
Siemens Healthineers
Silicon Biosystems
simfo GmbH
Stratos Genomics
Sysmex Inostics
Tempus Labs, Inc.
Thermo Fisher Scientific Inc.
Thrive Earlier Detection
Todos Medical
Vortex Biosciences
6. The Global Market for MDx Cancer
6.1 MDx Cancer – Global Market Overview by Country
6.1.1 Table – Global Market by Country
6.1.2 Chart - Global Market by Country
7. Global MDx Cancer Markets – By Type of Cancer
7.1 Global Market by Cancer Type - Overview
7.1.1 Table – Global Market by Cancer Type
7.1.2 Chart – Global Market by Cancer Type – Base/Final Comparison
7.1.3 Chart – Global Market by Cancer Type – Base Year
7.1.4 Chart – Global Market by Cancer Type –Final Year
7.1.5 Chart – Global Market by Cancer Type – Share by Year
7.2 MDx Breast Cancer
7.2.1 Table Breast Cancer Testing – by Country
7.2.2 Chart - Breast Cancer Testing Growth
7.3 MDx Colorectal Cancer
7.3.1 Table Colorectal Cancer Testing – by Country
7.3.2 Chart - Colorectal Cancer Testing Growth
7.4 MDx Cervical Cancer
7.4.1 Table Cervical Cancer Testing – by Country
7.4.2 Chart - Cervical Cancer Testing Growth
7.5 MDx Lung Cancer
7.5.1 Table Lung Cancer Testing – by Country
7.5.2 Chart - Lung Cancer Testing Growth
7.6 MDx Prostate
7.2.1 Table Prostate Testing – by Country
7.6.2 Chart - Prostate Testing Growth
7.7 MDx Melanoma Cancer
7.7.1 Table Melanoma Cancer Testing – by Country
7.7.2 Chart - Melanoma Cancer Testing Growth
7.8 MDx Blood
7.8.1 Table Blood Testing – by Country
7.8.2 Chart - Blood Testing Growth
7.9 MDx Companion Dx Development
7.9.1 Table Companion Dx Development – by Country
7.9.2 Chart - Companion Dx Development Growth
7.10 MDx Other Cancer
7.10.1 Table Other Cancer Testing – by Country
7.10.2 Chart - Other Cancer Testing Growth
8. Cancer Treatment and Trials
8.1 FDA Cancer Drug Approvals by Year
8.2 Clinical Trials Started 2010 to 2016
8.3 Prevalence of Cancer Treatments – 2015
I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests
Table of Tables
Table 1 Lab Spending 2014 to 2024
Table 2 Market Players by Type
Table 3 Clinical Laboratory Departments and Segments
Table 4 Laboratory Management Focus – Different Approaches
Table 5 Key Segmentation Variables Going Forward
Table 6 Five Factors Driving Growth
Table 7 Four Factors Limiting Growth
Table 8 Key Diagnostic Laboratory Technology Trends
Table 9 Next Generation Sequencing Technologies – Speed and Cost
Table 10 - Global MDx Cancer Market by Region
Table 11 Global Market by Cancer Type
Table 12 MDx Breast Cancer by Country
Table 13 MDx Colorectal Cancer by Country
Table 14 Cervical Cancer Testing by Country
Table 15 Lung Cancer Testing by Country
Table 16 Prostate Testing by Country
Table 17 Melanoma Cancer Testing by Country
Table 18 MDx Blood by Country
Table 19 MDx Companion Dx Development by Country
Table 20 MDx Other Cancer Testing by Country
Table 21 2020 Clinical Lab Fee Schedule
Table of Figures
Figure 1 Clinical Lab Spending 2014 to 2024
Figure 2 Growth in Aging Population
Figure 3 Death Rates from Cancer - USA
Figure 4 Comparing MDx Diagnostic and Traditional Testing
Figure 5 2018 Global Market Density Chart
Figure 6 MDx Market by Cancer - Base vs. Final
Figure 7 Cancer Market Base Year
Figure 8 Cancer Market Final Year
Figure 9 MDx Cancer Share by Year
Figure 10 Breast Cancer Testing Growth
Figure 11 Colorectal Cancer Testing Growth
Figure 12 Cervical Cancer Testing Growth
Figure 13 Lung Cancer Testing Growth
Figure 14 Prostate Testing Growth
Figure 15 Melanoma Cancer Testing Growth
Figure 16 Blood Testing Growth
Figure 17 Companion Dx Development Growth
Figure 18 Other Cancer Testing Growth
Figure 19 FDA Cancer Drug Approvals by Year
Figure 20 Clinical Trials for Immunotherapy by Year
Figure 21 Pie Chart of Prevalence of Cancer Treatments

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook